Living medicines represent a manufacturing challenge fundamentally different from traditional biologics. From microbiome therapeutics to phage therapy and engineered bacteria, these products require continuous viability maintenance, specialized GMP protocols for live organisms, and unbroken cold chain logistics, creating systematic bottlenecks that only a handful of companies can navigate.
Two critical tensions are reshaping commercialization strategy. First, manufacturing constraints threaten to create a two-tier system where only well, capitalized players with early CDMO partnerships or in-house capacity can compete. Second, the cold chain infrastructure these therapies demand directly conflicts with payer expectations for broad market access and cost-effectiveness.
With CDMO capacity scarce and regulatory pathways still evolving, success will belong to companies that solve manufacturing and commercialization simultaneously, not sequentially.
Key Discussion Points
- Manufacturing paradigm breaks: Living products demand real-time viability monitoring and AI-driven quality control as necessities, not optimizations—creating a CDMO capacity bottleneck that determines which companies can commercialize within realistic timeframes.
- The commercialization paradox: Unbroken cold chain requirements limit geographic reach and increase costs, directly conflicting with payer demands for cost-effectiveness and broad access—risking a system where living medicines remain niche therapies for privileged populations.
- Strategic positioning: Partnership decisions (in-house vs. CDMO vs. hybrid models) made today will separate market winners from clinical-stage assets trapped in manufacturing feasibility limbo for 3-5 years.
